Anti-inflammatory drugs and Alzheimer's disease

British Medical Journal

Volumn 327, Issue 7411, 2003, Pages 353-354

  Martyn, Christopher ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ARACHIDONIC ACID; ESTROGEN; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROGESTERONE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SULINDAC;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISEASE SEVERITY; EDITORIAL; ENZYME INHIBITION; HUMAN; MEMORY; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RISK ASSESSMENT;

EID: 0042733062     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.327.7411.353     Document Type: Editorial

References (11)

1. McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer's disease. Lancet 1999;335:1037.
2. In t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijin CM, Stijnen T, et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-21.
3. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003;327:128.
4. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of Rofecoxib or naproxen vs placebo on Alzheimer disease progression. JAMA 2003;289:2819-26.
5. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-64.
6. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001;414:212-6.
7. Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002;420:879-84.
8. Prevention of Alzheimer dementia and cognitive decline. Grant 7U01AG015477-03. Available at: http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen.
9. Inestrosa NC, Marzolo MP, Bonnefont AB. Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease. Mol Neurobiol 1998;17:73-86.
10. Shumaker SA, Legauh C, Thal L, Wallace RB, Ockene JK, Hendrix SL, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-62.
11. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the women's health initiative memory study: a randomized controlled trial. JAMA 2003;289:2663-72